Sarepta will sell back $50 million worth of shares to cover part of a $100 million milestone payment and its remaining shares worth $174 million.

NEW YORK – The European Research Council announced the newest recipients of its proof-of-concept grants last month and released a report reviewing the impact of the program since it first began ...

NEW YORK – Oric Pharmaceuticals will lay off 20 percent of its workforce to focus on advancing two lead drug candidates, including the brain-penetrant EGFR and HER2 exon 20 inhibitor enozertinib, the ...

Researchers at three Boston institutions are advancing a ctDNA assay with the goal of getting more children with solid tumors into biomarker-directed therapies and trials.

BUFFALO, New York – Five major research centers in New York have banded together to share resources and a manufacturing facility in a consortium aimed at developing new cell therapies for broader ...

NEW YORK – Bayer has entered into an exclusive global license agreement to develop and commercialize Kumquat's KRAS G12D inhibitor, KQB548, the companies announced Tuesday. Under the agreement, Bayer ...

The firm will explore FORX-428's activity in patients whose tumors harbor DNA damage repair mutations or mutations that cause high DNA replication stress.

Patients on a combination of toripalimab and RemeGen's anti-HER2 antibody disitamab vedotin fared better than those on a chemotherapy regimen.

Some oncologists and researchers have raised concerns about delays in the completion of confirmatory trials, but FDA now has new tools to push them ahead.